

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_79466
Title of the Manuscript:	A brief review on Viral Variants of Covid 19 infection
Type of the Article	REVIEW

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>I am honoured to review the manuscript Number: “Ms_JPRI_79466” entitled “A brief review on Viral Variants of Covid 19 infection” for the “Journal of Pharmaceutical Research International”.</p> <p>The authors presented a very interesting manuscript about the various variants of COVID-19. However, there are many errors and major revisions that the authors should do to merit publication in this journal.</p> <ol style="list-style-type: none"> 1) Please write COVID-19 it's not covid 19 or Covid 19 or COVID 19, even in the title! Please use “COVID-19” from the start until the end of the paper. 2) Please add a part where you study the new variant ‘omicron’ coronavirus. 3) There are some Run-on sentences, here are some examples of sentences to rephrase: <ul style="list-style-type: none"> • “The wild type virus mutated soon after a new strain emerged it contained a 29 nucleotide deletion in orf8 dubbed 29 following that a deletion of 82 nucleotides and 415 nucleotides in the same area were discovered” • “promotes immunological evasion by downregulating mhc i molecules according to a recent study” • “Pcr samples without the s gene were utilised to define variant b 1 1 7 there are 17 mutations in the viral genome of b 1 1 7” • “Has ten mutations l18f t20n p26s d138y r190s h655y t1027i v1176 k417t e484k and n501y rbd has three mutations l18f k417n and e484k which are identical to variation b 1 351” • Characteristics of mutations with unique genetic markers epsilon b 1 427 and b 1 429 zeta p 2 eta b 1 525 theta p 3 iota b 1 526 kappa b 1 617 1 and lambda b 1 617 1 • re the seven variations of interest voi described in the who weekly epidemiological report on june 22 2021 c 37 around june 2020 epsilon b 1 427 and b 1 429 variants commonly known as cal 20c/l452r • Specific mutations can be found in these versions b 1 427 l452r d614g b 1 429 s13i w152c l452r d614g the cdc has designated this strain as a variation of concern in the united states due to its high transmissibility 4) At the same time, there are some English errors, typos and grammatical mistakes, I advice you to make a round of revisions, please consider making your paper revised by a native English or even a Specialist. 5) There are some interesting papers that you did not cite, here are some examples of papers to add: <p>In Alpha variant, please specify that it can be especially harmful for people suffering from comorbitieis, diabetes and rheumatic diseases and add this reference:</p> <ul style="list-style-type: none"> • Aouissi, H. A., & Belhaouchet, I. (2021). What about rheumatic diseases and COVID-19?. New microbes and new infections, 41, 100846. https://doi.org/10.1016/j.nmni.2021.100846 <p>In Delta variant, consider also adding this manuscript:</p> <ul style="list-style-type: none"> • Shiehzadegan, S., Alaghemand, N., Fox, M., & Venketaraman, V. (2021). Analysis of the Delta Variant B.1.617.2 COVID-19. Clinics and practice, 11(4), 778–784. https://doi.org/10.3390/clinpract11040093 <p>Please add more details about the effect of Chinese vaccines, especially sinovac, and</p> 	<p>Dear Editor,</p> <p>I made corrections as per your suggestions. Thank you for review my paper.</p>

Review Form 1.6

	<p>cite these 2 papers:</p> <ul style="list-style-type: none">• Tao, Y. Y., Li, J. X., Hu, Y. M., Hu, Y. S., Zeng, G., & Zhu, F. C. (2021). Quadrivalent influenza vaccine (Sinovac Biotech) for seasonal influenza prophylaxis. Expert review of vaccines, 20(1), 1–11. https://doi.org/10.1080/14760584.2021.1875823• Palacios, R., Patiño, E. G., de Oliveira Pioreselli, R., Conde, M., Batista, A. P., Zeng, G., Xin, Q., Kallas, E. G., Flores, J., Ockenhouse, C. F., & Gast, C. (2020). Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(1), 853. https://doi.org/10.1186/s13063-020-04775-4 <p>6) Please try to change the way you have done your aim and objective, try to put them in a single paragraph rather than in 2 small titles .</p>	
Minor REVISION comments	<p>1) Concerning references, as it is a review article, please try to add more papers, approximately 10 others to make your review stronger.</p> <p>2) Consider also adding information about the selection of the articles in your review.</p> <p>3) Please Consider the fact of adding a prisma flow chart</p>	
Optional/General comments	<p>Have you checked that the review is original?</p>	

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	